Homocysteine status modifies the treatment effect of omega-3 fatty acids on cognition in a randomized clinical trial in mild to moderate Alzheimer’s disease: The OmegAD study

Manuscript Number: 

18-1148R2

Author(s): 
Hans Basun, Tommy Cederholm, Maria Eriksdotter, Gerd Faxen-Irving, Yvonne Freund-Levi, Erik Hjorth, Fredrik Jernerén, Jan Palmblad, Helga Refsum, Marianne Schultzberg, A. David Smith, Cheryl Turner, Lars-Olof Wahlund

Disclosures

Hans Basun

  • Nothing to Disclose

Tommy Cederholm

  • Lecture Fees:
    I do lectures at company organized educational efforts 3-5 times per year for companies Nutricia, Nestle, Fresenius-Kabi.

Maria Eriksdotter

  • Nothing to Disclose

Gerd Faxen-Irving

  • Nothing to Disclose

Yvonne Freund-Levi

  • Nothing to Disclose

Erik Hjorth

  • Nothing to Disclose

Fredrik Jernerén

  • Patents/Royalties
    I do have a patent pending (WO 2015/140545), but have not received any royalties or other financial benefits as a results from this patent application.

Jan Palmblad

  • Nothing to Disclose

Helga Refsum

  • Consulting Fees:
    Consult for P&G Healthcare International
    Patents/Royalties
    Named as inventor on patent US9364497B2 and on a patent application pending PCT/GB2015/050786.

Marianne Schultzberg

  • Nothing to Disclose

A. David Smith

  • Consulting Fees:
    Consult for P&G Personal Healthcare International
    Lecture Fees:
    I lecture with fee from Mylan Healthcare Norge AS
    Patents/Royalties
    Named as inventor on patents US6008221,US6127370,US9364497B2 and on a patent application pending PCT/GB2015/050786.

Cheryl Turner

  • Nothing to Disclose

Lars-Olof Wahlund

  • Nothing to Disclose